Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has begun the manufacturing process for the distributable version of its patented transplant technology. The transplant blood test is a method of checking for signs of graft damage in transplant recipients, the assay measures levels of donor derived cell-free DNA (dd-cfDNA) in the blood. Early access for this RUO kit is expected to open in late Q4 2023.
“We believe that our patented method of assessing graft damage offers distinct benefits over competing and more invasive approaches,” says Josh Riggs, Oncocyte’s CEO. “Oncocyte is committed to being a partner for the transplant community. Our test provides a simple, easy-to-use workflow, on droplet digital PCR, so researchers can perform in-house dd-cfDNA testing. We believe opening access to our technology supports broader research than what is addressable with today’s centralized testing. We look forward to updating investors on rapid manufacturing progress as we move to commercialization.”
The transplant blood test can typically be accomplished within the same day, without the necessity of donor genotyping. Results will be provided in both percentage and precise quantification of dd-cfDNA.
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft is a blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and pipeline test DetermaCNI is a blood-based monitoring tool for assessing therapeutic efficacy in cancer patients.
